Alasdair Thong
Founding Partner @ Selvedge Venture
London, United Kingdom
Alasdair Thong is a seed investor at Selvedge Venture in London focused on Medical and Health Care. Alasdair Thong is the Founding Partner of Selvedge Venture. He previously worked at Luminous Ventures as a Venture Partner. Alasdair Thong attended the University of Cambridge.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Alasdair Thong invests in
Stages Alasdair Thong invests in
Countries Alasdair Thong invests in
Investment Focus
Industry
- Medical 2 (25%)
- Health Care 2 (25%)
- Life Science 2 (25%)
- Wellness 1 (13%)
- Neuroscience 1 (13%)
Stage
- Seed 3 (38%)
- Pre-Seed 1 (13%)
- Series A 1 (13%)
- Funding Round 1 (13%)
- Venture - Series Unknown 1 (13%)
Country
- United Kingdom 3 (38%)
- Denmark 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Alcolase
|
Alcolase is a Danish life science start-up that specializes in alcohol flushing. | $1.7M / Seed / May 18, 2026 | |
BIOS
|
BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer forprecision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life.Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board). | Jun 22, 2023 | |
|
BIOS
|
BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer forprecision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life.Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board). | $20M / Series A / Jun 22, 2023 | |
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Pre-Seed / Apr 25, 2022 | |
|
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Pre-Seed / Apr 25, 2022 | |
|
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Seed / Apr 25, 2022 | |
Oxford Medical Products
|
Oxford Medical Products is developing a safe, effective and affordable breakthrough technology for weight loss that uses a self-expanding capsule which occupies space in the stomach, reducing hunger and leading to significant weight loss. Led by a team of scientists, medical professionals, and entrepreneurs who have come together to solve one ofthe world’s toughest and most urgent medical challenges. | $3.3M / Venture - Series Unknown / Mar 09, 2022 | |
|
Oxford Medical Products
|
Oxford Medical Products is developing a safe, effective and affordable breakthrough technology for weight loss that uses a self-expanding capsule which occupies space in the stomach, reducing hunger and leading to significant weight loss. Led by a team of scientists, medical professionals, and entrepreneurs who have come together to solve one ofthe world’s toughest and most urgent medical challenges. | $1.6M / Seed / Mar 24, 2021 |
Co-Investors
About Selvedge Venture
Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.
Selvedge Venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alasdair Thong
Founding Partner
|
|||
Angelos Spiliopoulos
Business Analyst
|
|||
Esra Berkol
Head of Investor Relations
|
|||
Robert Thong
Venture Development Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Alasdair Thong invest in?
Alasdair Thong invests primarily in Medical, Health Care and Life Science startups, most often at Seed and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alasdair Thong last invest?
The most recent investment recorded for Alasdair Thong closed in May 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
